Flux analysis resolves distinct brain uptake and clearance of TfR- and CD98hc-targeting large molecules

Advances in large-molecule delivery across the blood-brain barrier (BBB) by targeting receptors such as transferrin receptor (TfR) or CD98 heavy chain (CD98hc) are shifting the focus from restricted parenchymal access toward brain exposure profiles tailored to therapeutic needs. However, brain concentrations offer only partial insight into delivery mechanisms, as they reflect the net balance of two dynamic processes: flux of molecules entering and leaving the brain, here termed brain uptake and brain clearance, respectively. Here, we establish a generalizable experimental and mathematical modeling framework to resolve these opposing fluxes and demonstrate its application using pharmacokinetic (PK) data from Fc-engineered antibody transport vehicles (ATVs) targeting TfR or CD98hc in humanized knock-in mouse models. First, to directly estimate brain clearance, we engineered anti-ATV antibodies that selectively bind the TV patch to block receptor-mediated brain uptake in vivo. Integrating these measurements with a mechanistic PK model, we then reconstructed brain fluxes of ATV molecules over time across a broad range of receptor affinities. Results demonstrated that TfR-targeting promotes rapid, affinity-dependent brain uptake accompanied by comparatively rapid brain clearance, whereas CD98hc-targeting results in slower brain uptake and prolonged retention. Extending this framework to dual TfR/CD98hc-targeting ATVs suggested that higher observed brain exposure relative to single-receptor formats does not necessarily translate to greater brain delivery: increased exposure was predicted to arise primarily from reduced brain clearance, associated with CD98hc-mediated retention, rather than enhanced uptake through dual-receptor engagement. Together, these results establish a quantitative basis for resolving brain fluxes and engineering brain-targeted biologics for desired therapeutic outcomes.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.12.766279
Primary Topic
Barrier Structure and Function Studies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Flux analysis resolves distinct brain uptake and clearance of TfR- and CD98hc-targeting large molecules

Mihalis S. Kariolis, Robert G. Thorne, Abira Bandyopadhyay, Robert C. Wells et al.
5 links
bioRxiv (Cold Spring Harbor Laboratory)
Barrier Structure and Function Studies
preprint

Flux analysis resolves distinct brain uptake and clearance of TfR- and CD98hc-targeting large molecules

Mihalis S. Kariolis, Robert G. Thorne, Abira Bandyopadhyay, Robert C. Wells, Annie Arguello, Nathalie Khoury, Kendra J. Lechtenberg, Lionel Rougé, Roni Chau, Johann Chow, Nicholas P. D. Liau, Ellen Y. T. Chien, Christopher M. Koth, Yaneth Robles‐Colmenares, Mahdiar Sadeghi, Kylie S. Chew, Kirk R. Henne, Cathal S. Mahon, Jennifer E. Kung, Michelle E. Pizzo, Joseph W. Lewcock, Padma Akkapeddi, J Sauer, Ryan J. Watts, Arash Moshkforoush, Mark S. Dennis, Kaitlin Xa, Kevin Rebadulla, Hiwot Misker, Tiffany Tran, Hoang Nguyen, Isabel Becerra, Do Jin Kim, Darren Chan, David Huynh, Ahlam Qerqez, Ranya K. A. Virk, Don Zhong, Allisa Clemens, Kapil Gadkar, Richard Theolis, Butch Benitez, Joseph Duque, Shyeilla Dhuria, Y. Joy Yu Zuchero, Eric Liang
preprint en

Abstract

Advances in large-molecule delivery across the blood-brain barrier (BBB) by targeting receptors such as transferrin receptor (TfR) or CD98 heavy chain (CD98hc) are shifting the focus from restricted parenchymal access toward brain exposure profiles tailored to therapeutic needs. However, brain concentrations offer only partial insight into delivery mechanisms, as they reflect the net balance of two dynamic processes: flux of molecules entering and leaving the brain, here termed brain uptake and brain clearance, respectively. Here, we establish a generalizable experimental and mathematical modeling framework to resolve these opposing fluxes and demonstrate its application using pharmacokinetic (PK) data from Fc-engineered antibody transport vehicles (ATVs) targeting TfR or CD98hc in humanized knock-in mouse models. First, to directly estimate brain clearance, we engineered anti-ATV antibodies that selectively bind the TV patch to block receptor-mediated brain uptake in vivo. Integrating these measurements with a mechanistic PK model, we then reconstructed brain fluxes of ATV molecules over time across a broad range of receptor affinities. Results demonstrated that TfR-targeting promotes rapid, affinity-dependent brain uptake accompanied by comparatively rapid brain clearance, whereas CD98hc-targeting results in slower brain uptake and prolonged retention. Extending this framework to dual TfR/CD98hc-targeting ATVs suggested that higher observed brain exposure relative to single-receptor formats does not necessarily translate to greater brain delivery: increased exposure was predicted to arise primarily from reduced brain clearance, associated with CD98hc-mediated retention, rather than enhanced uptake through dual-receptor engagement. Together, these results establish a quantitative basis for resolving brain fluxes and engineering brain-targeted biologics for desired therapeutic outcomes.

bioRxiv (Cold Spring Harbor Laboratory)
Denali Therapeutics (United States) (US)
Good health and well-being
Barrier Structure and Function Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon